Motherisk Update: Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy

Canadian Family Physician

Volumn 51, Issue MAY, 2005, Pages 667-668

  Shrim, Alan ^a   Koren, Gideon ^a,b  

^a Motherisk Program   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DEVELOPMENTAL DISORDER; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG USE; FALLOT TETRALOGY; FAMILY PLANNING; FEMALE; FETOTOXICITY; HUMAN; HYPOTHYROIDISM; INTESTINE MALROTATION; MATERNAL CARE; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY TERMINATION; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; TERATOGENICITY; CONGENITAL MALFORMATION; ENVIRONMENTAL EXPOSURE; IMMUNOLOGY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MATERNAL EXPOSURE; PREGNANCY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18844362944     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004;27(5):307-24.
2. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001;96(7):2274-5.
3. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99(12):2385-92.
4. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30(2):241-6.